PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué... July 13, 2022 A Penny for Your Thoughts August 17, 2021 MAP Congress 2020: Molecular Analysis for Precision Oncology October 2, 2020 Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 Load more HOT NEWS Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix Getting cancer services back on track during the COVID-19 pandemic
